Amarin (AMRN)
(Delayed Data from NSDQ)
$0.87 USD
+0.01 (1.72%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.90 +0.03 (2.87%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 201 - 220 ( 353 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Positive REDUCE-IT Results Presented at American College of Cardiology 2019 Meeting; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Expect the Continued Underlying Vascepa Demand to Drive Value; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Takeaways From the Amarin Management Breakfast During the 2019 JPM Healthcare Conference; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Embracing a Decidedly Non-Orphan Disease Company; Reit Buy and Raising PT to $51
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
In Anticipation of AHA, We Reit Buy and Raise PT to $31
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
REDUCE-IT Results Even Stronger than Our Best Case Scenario; Reit Buy and Raising PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Favorable Risk/Return Profile Ahead of REDUCE-IT Topline; Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
2018 Ought to Mark End of a Long Journey (or a New Beginning); Reit Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
3Q Update: Getting Our Ducks in a Row Ahead of REDUCE-IT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
We Believe There Is Now an Attractive Entry Point Heading Into Interim Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
CANTOS Study Further Validates Mechanism and Commercial Upside to REDUCE-IT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Historical Rx Review Suggests Limited Downside to Vascepa Underlying Revenue From Potential REDUCE-IT Miss
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
1Q Update: Events Tracking to Expectation, Focus Remains on REDUCE-IT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Continued Uptick in Vascepa Scripts to Support a Cash Flow Positive 2017
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
REDUCE-IT Stays on the Right Side of the Track: 1Q16 Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A